Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Erratum

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo, Italy; Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo
Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino
Universitè Paris Citè, Paris, France; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris
Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino
Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino
CHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d’Hématologie Clinique et Thérapie Cellulaire, Pessac
University Grenoble Alpes, Institute For Advanced Biosciences, INSERM U1209, CNRS UMR 5309, University Hospital, Molecular Biology and Hematology Departments, Grenoble
Ematologia AOU delle Marche, Ancona
Department of Hematology, Centre Henri Becquerel, Rouen
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo
Fondazione Italiana Linfomi ETS, Modena
Azienda Unitá Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia
Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese
Nantes University Hospital and CRC2 NA, Nantes
UO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria
Universitè Paris Citè, Paris
Dipartimento di Medicina e Chirurgia, Universitá di Parma, AOU di Parma, Parma
Ematologia AOU delle Marche, Ancona
Department of Hematology, Ravenna Hospital, Ravenna
Hematology Unit, IRCCS Regina Elena National Cancer Institute, Roma
Laboratoire d’Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon
Service d’Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon
Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo
Oncohematology Unit, University of Perugia, Azienda Ospedaliera S. Maria, Terni
Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”- IRST, Meldola
Ospedale Oncologico A. Businco, Cagliari
U.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo
CHIMOMO Department, University of Modena and Reggio Emilia, Modena
La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo
University of Eastern Piedmont, Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria
IOSI, Oncology Institute of Southern Switzerland and IOR, Institute of Oncology Research IELSG International Extranodal Lymphoma Study, Bellinzona
Universitè Paris Citè, Paris, France; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris
Vol. 110 No. 4 (2025): April, 2025 https://doi.org/10.3324/haematol.2024.287031

In the article by Iannitto E et al.,1 entitled “Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study”, an author affiliation was incomplete. The affiliation of the 22nd author should be stated as: Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy, and not Ematologia, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy.

Footnotes

  • Received November 22, 2024
  • Accepted November 22, 2024

Correspondence

E. Iannitto emilio.iannitto@gmail.com

References

  1. Iannitto E, Ferrero S, Bommier C. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Haematologica. 2024; 109(7):2297-2302. https://doi.org/10.3324/haematol.2023.284109|PubMed|PubMed Central|Google Scholar

Article Information

Vol. 110 No. 4 (2025): April, 2025 : Erratum
 
DOI
https://doi.org/10.3324/haematol.2024.287031
Pubmed
40165734
Pubmed Central
PMC11959258
 
Published
2025-04-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2025 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
579
PDF Downloads
294

Statistics from Altmetric.com

Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2025 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online